Health Canada still reviewing data on antiviral COVID-19 drug approved in U.K.

The regulator said its review will determine whether benefits of using the drug outweigh risks and ensure it meets “stringent safety, efficacy and quality requirements.”

(Melissa Couto Zouber/ CTV News) –– Health Canada says it’s still reviewing data on an antiviral COVID-19 drug that was authorized Thursday in the United Kingdom.

The federal regulator said it continues to receive data “as new information becomes available” from pharmaceutical company Merck on their drug molnupiravir, considered the first pill to successfully treat COVID-19.

It offered no timeline for completion of the review process.

“As the review is still ongoing, it is not possible to predict when a regulatory decision will be made,” Health Canada stated by email. (…)

READ MORE

Categories

Categories